vs

Side-by-side financial comparison of MITEK SYSTEMS INC (MITK) and Zymeworks Inc. (ZYME). Click either name above to swap in a different company.

MITEK SYSTEMS INC is the larger business by last-quarter revenue ($44.2M vs $27.6M, roughly 1.6× Zymeworks Inc.). MITEK SYSTEMS INC runs the higher net margin — 6.3% vs -71.0%, a 77.3% gap on every dollar of revenue. On growth, Zymeworks Inc. posted the faster year-over-year revenue change (72.6% vs 18.8%). MITEK SYSTEMS INC produced more free cash flow last quarter ($6.6M vs $-31.8M).

Mitek Systems, Inc. is a software company that specializes in digital identity verification and mobile image processing using artificial intelligence. The company's software is used for depositing checks and opening bank accounts via mobile devices. It also verifies identity documents such as passports, ID cards, and driver's licenses by analyzing a selfie of an individual holding their ID, comparing their face to the photo on the document.

Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...

MITK vs ZYME — Head-to-Head

Bigger by revenue
MITK
MITK
1.6× larger
MITK
$44.2M
$27.6M
ZYME
Growing faster (revenue YoY)
ZYME
ZYME
+53.8% gap
ZYME
72.6%
18.8%
MITK
Higher net margin
MITK
MITK
77.3% more per $
MITK
6.3%
-71.0%
ZYME
More free cash flow
MITK
MITK
$38.4M more FCF
MITK
$6.6M
$-31.8M
ZYME

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
MITK
MITK
ZYME
ZYME
Revenue
$44.2M
$27.6M
Net Profit
$2.8M
$-19.6M
Gross Margin
Operating Margin
12.3%
-80.1%
Net Margin
6.3%
-71.0%
Revenue YoY
18.8%
72.6%
Net Profit YoY
160.1%
34.3%
EPS (diluted)
$0.06
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MITK
MITK
ZYME
ZYME
Q4 25
$44.2M
Q3 25
$44.8M
$27.6M
Q2 25
$45.7M
$48.7M
Q1 25
$51.9M
$27.1M
Q4 24
$37.3M
$31.0M
Q3 24
$43.2M
$16.0M
Q2 24
$45.0M
$19.2M
Q1 24
$47.0M
$10.0M
Net Profit
MITK
MITK
ZYME
ZYME
Q4 25
$2.8M
Q3 25
$1.9M
$-19.6M
Q2 25
$2.4M
$2.3M
Q1 25
$9.2M
$-22.6M
Q4 24
$-4.6M
$-23.5M
Q3 24
$8.6M
$-29.9M
Q2 24
$216.0K
$-37.7M
Q1 24
$282.0K
$-31.7M
Operating Margin
MITK
MITK
ZYME
ZYME
Q4 25
12.3%
Q3 25
10.5%
-80.1%
Q2 25
8.3%
-1.4%
Q1 25
21.9%
-94.5%
Q4 24
-8.3%
-71.6%
Q3 24
17.8%
-213.8%
Q2 24
1.6%
-222.9%
Q1 24
1.5%
-376.9%
Net Margin
MITK
MITK
ZYME
ZYME
Q4 25
6.3%
Q3 25
4.2%
-71.0%
Q2 25
5.2%
4.8%
Q1 25
17.6%
-83.5%
Q4 24
-12.4%
-75.8%
Q3 24
19.8%
-186.6%
Q2 24
0.5%
-195.8%
Q1 24
0.6%
-315.6%
EPS (diluted)
MITK
MITK
ZYME
ZYME
Q4 25
$0.06
Q3 25
$0.04
$-0.26
Q2 25
$0.05
$0.03
Q1 25
$0.20
$-0.30
Q4 24
$-0.10
$-0.32
Q3 24
$0.19
$-0.39
Q2 24
$0.00
$-0.49
Q1 24
$0.01
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MITK
MITK
ZYME
ZYME
Cash + ST InvestmentsLiquidity on hand
$190.1M
$64.8M
Total DebtLower is stronger
$4.8M
Stockholders' EquityBook value
$233.7M
$320.1M
Total Assets
$446.5M
$397.3M
Debt / EquityLower = less leverage
0.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MITK
MITK
ZYME
ZYME
Q4 25
$190.1M
Q3 25
$193.0M
$64.8M
Q2 25
$167.1M
$98.3M
Q1 25
$136.2M
$76.2M
Q4 24
$121.2M
$66.1M
Q3 24
$130.3M
$122.4M
Q2 24
$123.1M
$71.0M
Q1 24
$123.9M
$114.8M
Total Debt
MITK
MITK
ZYME
ZYME
Q4 25
$4.8M
Q3 25
$4.3M
Q2 25
Q1 25
Q4 24
Q3 24
$2.7M
Q2 24
Q1 24
Stockholders' Equity
MITK
MITK
ZYME
ZYME
Q4 25
$233.7M
Q3 25
$240.3M
$320.1M
Q2 25
$237.6M
$334.5M
Q1 25
$220.2M
$325.0M
Q4 24
$200.9M
$338.8M
Q3 24
$214.8M
$367.0M
Q2 24
$209.6M
$406.2M
Q1 24
$216.1M
$438.0M
Total Assets
MITK
MITK
ZYME
ZYME
Q4 25
$446.5M
Q3 25
$459.1M
$397.3M
Q2 25
$446.7M
$408.4M
Q1 25
$425.3M
$425.5M
Q4 24
$396.0M
$463.1M
Q3 24
$413.8M
$487.2M
Q2 24
$409.2M
$515.6M
Q1 24
$417.0M
$553.8M
Debt / Equity
MITK
MITK
ZYME
ZYME
Q4 25
0.02×
Q3 25
0.02×
Q2 25
Q1 25
Q4 24
Q3 24
0.01×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MITK
MITK
ZYME
ZYME
Operating Cash FlowLast quarter
$8.0M
$-31.4M
Free Cash FlowOCF − Capex
$6.6M
$-31.8M
FCF MarginFCF / Revenue
14.9%
-115.2%
Capex IntensityCapex / Revenue
3.2%
1.5%
Cash ConversionOCF / Net Profit
2.89×
TTM Free Cash FlowTrailing 4 quarters
$60.5M
$-65.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MITK
MITK
ZYME
ZYME
Q4 25
$8.0M
Q3 25
$19.5M
$-31.4M
Q2 25
$21.6M
$12.1M
Q1 25
$13.7M
$-3.4M
Q4 24
$565.0K
$-41.5M
Q3 24
$21.1M
$-5.9M
Q2 24
$13.0M
$-25.0M
Q1 24
$7.1M
$-37.7M
Free Cash Flow
MITK
MITK
ZYME
ZYME
Q4 25
$6.6M
Q3 25
$19.2M
$-31.8M
Q2 25
$21.2M
$11.6M
Q1 25
$13.5M
$-3.4M
Q4 24
$230.0K
$-41.8M
Q3 24
$20.8M
$-6.8M
Q2 24
$12.6M
$-25.6M
Q1 24
$6.6M
$-37.9M
FCF Margin
MITK
MITK
ZYME
ZYME
Q4 25
14.9%
Q3 25
42.9%
-115.2%
Q2 25
46.5%
23.7%
Q1 25
26.0%
-12.6%
Q4 24
0.6%
-134.8%
Q3 24
48.2%
-42.4%
Q2 24
27.9%
-133.0%
Q1 24
14.0%
-377.5%
Capex Intensity
MITK
MITK
ZYME
ZYME
Q4 25
3.2%
Q3 25
0.6%
1.5%
Q2 25
0.7%
1.1%
Q1 25
0.4%
0.1%
Q4 24
0.9%
1.0%
Q3 24
0.7%
5.6%
Q2 24
1.0%
3.1%
Q1 24
1.0%
1.8%
Cash Conversion
MITK
MITK
ZYME
ZYME
Q4 25
2.89×
Q3 25
10.46×
Q2 25
9.00×
5.21×
Q1 25
1.50×
Q4 24
Q3 24
2.46×
Q2 24
60.12×
Q1 24
25.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MITK
MITK

Fraud And Identity Solutions$25.5M58%
License$13.9M31%
Fraud And Identity Solutions Software License And Support$3.9M9%
Professional Services And Other$1.2M3%

ZYME
ZYME

Segment breakdown not available.

Related Comparisons